Spago Nanomedical on the progress with Tumorad

Spago Nanomedical on the progress with Tumorad

28 January, 2022This week, Lund-based Spago Nanomedical presented positive preclinical data in its cancer treatment project Tumorad. After treatment with the candidate 177Lu-SN201, a significant reduction in tumour growth was shown in a colorectal cancer model. In addition, the survival was extended by 39 per cent compared to the control group. BioStock contacted CEO Mats … Continue reading Spago Nanomedical on the progress with Tumorad